Key Takeaway: The Bio Report podcast features Fred Aslan, CEO of Artiva Biotherapeutics, discussing the advantages of off-the-shelf NK cell therapies. These therapies, part of the innate immune system, offer a safer alternative to CAR-T therapies by avoiding cytokine storms and reducing costs. The potential applications for these therapies extend beyond cancer to autoimmune diseases.
Price reaction · baseline $4.39 (2025-03-04 close) · hit pre-market · clean, no other ARTV news in the window
day 0 close · peak
+2.3%
Market Sentiment Analysis
POSITIVE FACTORS
NK cells can be used off-the-shelf without genetic modifications.
They have a lower risk of triggering cytokine storms compared to CAR-T therapies.
NK cell therapies are more cost-effective and safer.
They have potential applications beyond cancer, including autoimmune diseases.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+215%
120-day peak, hindsight
Typical move
13.1%
average across 2 past catalysts
Cash runway
~51 mo
Minimal dilution risk
Lead asset
Allogeneic NK Cells
Phase 2 · Refractory Rheumatoid Arthritis (RA)
Full Press Release Details
NK cells, part of the innate immune system, serve as the body’s first line of defense. These cells can recognize and kill abnormal or infected cells. As therapies, they have the advantage over CAR-T and other cell therapies because they can be used off-the-shelf without undergoing gene editing or other genetic modifications. They also don’t trigger cytokine storms, a common reaction to CAR-T therapies that can cause a systemic inflammatory response that can range from flu-like symptoms to life-threatening complications. The greater safety and lower costs of these NK cell therapies open the door to broader uses beyond cancer to include autoimmune diseases.
In this podcast with The Bio Report, Fred Aslan, President and CEO of Artiva Biotherapeutics, talks about the company’s off-the-shelf NK cell therapies, the case for pairing them with monoclonal antibodies, and how they can broaden the uses for cell therapies.
Listen here.
Frequently Asked Questions
What are NK cells?
NK cells are part of the innate immune system and help defend against abnormal or infected cells.
How do NK cell therapies differ from CAR-T therapies?
NK cell therapies can be used off-the-shelf and do not require genetic modifications, unlike CAR-T therapies.
What are the advantages of NK cell therapies?
They are safer, more cost-effective, and have a lower risk of causing cytokine storms.
Can NK cell therapies be used for autoimmune diseases?
Yes, NK cell therapies have potential applications beyond cancer, including autoimmune diseases.